Loading clinical trials...
Loading clinical trials...
Frequency of Tuberculosis in Psoriasis Patients Using Anti-TNF Therapy During 15 Years of Follow-up.
Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center.
Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center. TNF inhibitor therapy may increase the risk for tuberculosis infection. According to medical data in our hospital in last 15 years, tuberculosis rate of psoriasis patients receiving etanercept, adalimumab and infliximab will be compared.
Age
18 - 100 years
Sex
ALL
Healthy Volunteers
No
Bezmialem Vakif University Hospital
Istanbul, Turkey (Türkiye)
Start Date
May 1, 2023
Primary Completion Date
July 31, 2023
Completion Date
July 31, 2023
Last Updated
August 21, 2024
719
ACTUAL participants
Lead Sponsor
Bezmialem Vakif University
NCT06192160
NCT05947890
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05989802